Randomised phase II trial of olaparib, chemotherapy or olaparib and cediranib in patients with platinum-resistant ovarian cancer (OCTOVA): a study protocol
Introduction Patients relapsing within 12 months of platinum-based chemotherapy usually have a poorer response to subsequent treatments. To date, extensive research into the mechanism of resistance to platinum agents in the treatment of ovarian cancer has not resulted in improved responses or longer...
Main Authors: | Rachel Dunn, Anita Mansouri, Naomi McGregor, Sam Dobbie, Jane Holmes, Linda Collins |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2021-01-01
|
Series: | BMJ Open |
Online Access: | https://bmjopen.bmj.com/content/11/1/e041463.full |
Similar Items
-
CECs and IL-8 have prognostic and predictive utility in patients with recurrent platinum-sensitive ovarian cancer: biomarker correlates from the randomized phase 2 trial of olaparib and cediranib compared with olaparib in recurrent platinum-sensitive ovarian cancer
by: Jung-Min eLee, et al.
Published: (2015-06-01) -
Combination of triapine, olaparib, and cediranib suppresses progression of BRCA-wild type and PARP inhibitor-resistant epithelial ovarian cancer.
by: Z Ping Lin, et al.
Published: (2018-01-01) -
Olaparib in the management of ovarian cancer
by: Bixel K, et al.
Published: (2015-08-01) -
Olaparib as maintenance treatment for patients with platinum-sensitive relapsed ovarian cancer
by: Jonathan A. Ledermann, et al.
Published: (2019-05-01) -
Olaparib maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer
by: S V Khokhlova
Published: (2017-09-01)